Literature DB >> 6625981

A working protocol to be used as a guideline for trials in multiple sclerosis.

H L Weiner, G W Ellison.   

Abstract

Entities:  

Mesh：

Year:  1983        PMID： 6625981     DOI： 10.1001/archneur.1983.04050100044018

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  7 in total

1.  T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis.

Authors:  J R Oksenberg; M Sherritt; A B Begovich; H A Erlich; C C Bernard; L L Cavalli-Sforza; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.

Authors:  G F Siracusa; M P Amato; L Fratiglioni; D Sità; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1987-12

3.  Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism.

Authors:  C N Gaiser; M J Johnson; G de Lange; L Rassenti; L L Cavalli-Sforza; L Steinman
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

4.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

5.  Multiple sclerosis: failure of treatment with verapamil in a pilot trial.

Authors:  S Komoly; G Jakab; A Fazekas
Journal:  J Neurol       Date:  1986-02       Impact factor: 4.849

6.  Effectiveness of azathioprine treatment in multiple sclerosis.

Authors:  L Fratiglioni; G F Siracusa; M P Amato; D Sità; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1988-06

Review 7.  Iron chelation and multiple sclerosis.

Authors:  Kelsey J Weigel; Sharon G Lynch; Steven M LeVine
Journal:  ASN Neuro       Date:  2014-01-30       Impact factor: 4.146
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.